CMC holdup delays Iovance filing again — to 2022 — as FDA seeks more assay data for TIL therapy
Remember those potency assays that tripped up Iovance’s preparations for a BLA filing? It turns out they may take even longer than expected to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
